Androgen deprivation therapy Archives

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Trial

RADICALS-HD

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:17

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Trial

Phase 3, PRESTO

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:13

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March 2022 07:21

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:27

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By

Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France

Trial

Phase 3, PEACE-1

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

Intrinsic tumour biology may be predictive of treatment response in prostate cancer

Presented By

Prof. Felix Feng, University of California San Francisco, USA

Trial

Phase 3, SPARTAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Final TITAN trial results favour use of apalutamide

Presented By

Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada

Trial

Phase 3, TITAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Abiraterone in M1 hormone-naïve prostate cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:51

Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Presented By

Dr Kim N. Chi, BC Cancer Agency, Canada

Trial

Phase 3, TITAN

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:28